Litcius/Paper detail

212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC)

Sara M. Tolaney, A. Chan, Katarína Petráková, Suzette Delaloge, Mario Campone, Hitoshi Iwata, Parvin F. Peddi, Peter A. Kaufman, Elisabeth De Kermadec, Q. Liu, Pascale A. Cohen, Gautier Paux, S-A. Im

2022Annals of Oncology18 citationsDOI

Topics & Concepts

MedicineFulvestrantClinical endpointInternal medicineOncologyProgression-free survivalMetastatic breast cancerBreast cancerTamoxifenCancerHazard ratioPhases of clinical researchRandomized controlled trialGynecologyChemotherapyConfidence intervalAdvanced Breast Cancer TherapiesCancer Treatment and PharmacologyHER2/EGFR in Cancer Research
212MO AMEERA-3, a phase II study of amcenestrant (AMC) versus endocrine treatment of physician’s choice (TPC) in patients (pts) with endocrine-resistant ER+/HER2− advanced breast cancer (aBC) | Litcius